Janice Mehnert: Adjuvant therapy appears to benefit patients with acral, but not mucosal, melanoma

Janice Mehnert, Associate Director For Clinical Research at Perlmutter Cancer Center of NYU Langone Health/NYU Grossman School of Medicine, shared a post on X/Twitter:

“First paper of 2024! In a retrospective analysis, adjuvant therapy appears to benefit patients with acral, but not mucosal, melanoma. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based th…”

Read further.

Source: Janice Mehnert/X